143 related articles for article (PubMed ID: 17162129)
41. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
[TBL] [Abstract][Full Text] [Related]
42. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
43. The long term outcome of papillary thyroid carcinoma patients without primary central lymph node dissection: expected improvement of routine dissection.
Giles Senyurek Y; Tunca F; Boztepe H; Alagöl F; Terzioglu T; Tezelman S
Surgery; 2009 Dec; 146(6):1188-95. PubMed ID: 19958948
[TBL] [Abstract][Full Text] [Related]
44. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
45. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
46. Pattern of anterolateral cervical lymph nodes involvement in papillary thyroid carcinoma.
Iqbal T; Zareen M; Iqbal A; Tahir F; Khan S; Ahmed Z
J Coll Physicians Surg Pak; 2009 Feb; 19(2):104-7. PubMed ID: 19208314
[TBL] [Abstract][Full Text] [Related]
47. Altered expression of cyclins and cell cycle inhibitors in papillary thyroid cancer: prognostic implications.
Pickett CA; Agoff SN; Widman TJ; Bronner MP
Thyroid; 2005 May; 15(5):461-73. PubMed ID: 15929668
[TBL] [Abstract][Full Text] [Related]
48. Clinical significance of p53 protein expression in papillary thyroid carcinoma.
Morita N; Ikeda Y; Takami H
World J Surg; 2008 Dec; 32(12):2617-22. PubMed ID: 18836853
[TBL] [Abstract][Full Text] [Related]
49. Apoptosis and proliferation related molecules (Bcl-2, Bax, p53, PCNA) in papillary microcarcinoma versus papillary carcinoma of the thyroid.
Cvejic D; Selemetjev S; Savin S; Paunovic I; Petrovic I; Tatic S
Pathology; 2008 Aug; 40(5):475-80. PubMed ID: 18604733
[TBL] [Abstract][Full Text] [Related]
50. Routine bilateral central lymph node clearance for papillary thyroid cancer.
Sadowski BM; Snyder SK; Lairmore TC
Surgery; 2009 Oct; 146(4):696-703; discussion 703-5. PubMed ID: 19789029
[TBL] [Abstract][Full Text] [Related]
51. Predictive value of p53 and PCNA expression for occult neck metastases in patients with clinically node-negative oral tongue cancer.
Keum KC; Chung EJ; Koom WS; Cho JH; Cho SH; Choi EC; Lee CG; Suh CO; Kim GE
Otolaryngol Head Neck Surg; 2006 Dec; 135(6):858-64. PubMed ID: 17141074
[TBL] [Abstract][Full Text] [Related]
52. [Clinical and pathological analysis of central compartment dissection in patients with papillary thyroid cancer with negative clinical lymph node metastasis].
Fu JY; Wu Y; Wang ZY; An Y; Sun TQ; Xiang J
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):470-2. PubMed ID: 17686305
[TBL] [Abstract][Full Text] [Related]
53. Expression and function of the chemokine receptor CCR7 in thyroid carcinomas.
Sancho M; Vieira JM; Casalou C; Mesquita M; Pereira T; Cavaco BM; Dias S; Leite V
J Endocrinol; 2006 Oct; 191(1):229-38. PubMed ID: 17065406
[TBL] [Abstract][Full Text] [Related]
54. Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma.
Baek SK; Woo JS; Kwon SY; Lee SH; Chae YS; Jung KY
Laryngoscope; 2007 May; 117(5):911-6. PubMed ID: 17473695
[TBL] [Abstract][Full Text] [Related]
55. High recurrent rate of multicentric papillary thyroid carcinoma.
Lin JD; Chao TC; Hsueh C; Kuo SF
Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
[TBL] [Abstract][Full Text] [Related]
56. Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax, and bcl-2 in oral lichen planus and oral squamous cell carcinoma.
de Sousa FA; Paradella TC; Carvalho YR; Rosa LE
Ann Diagn Pathol; 2009 Oct; 13(5):308-12. PubMed ID: 19751907
[TBL] [Abstract][Full Text] [Related]
57. [The characteristics of papillary thyroid cancer lymph node metastasis and the clinical significance of central region cervical lymph node dissection].
Li Z; Qu XC; Cheng B
Zhonghua Wai Ke Za Zhi; 2008 Sep; 46(18):1407-9. PubMed ID: 19094514
[TBL] [Abstract][Full Text] [Related]
58. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
59. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
Sahoo S; Hoda SA; Rosai J; DeLellis RA
Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
[TBL] [Abstract][Full Text] [Related]
60. [Thyroglobulin levels in needle lymph node cytology for the detection of papillary thyroid cancer recurrence].
Véliz J; Brantes S; Ramos C; Aguayo J; Cáceres E; Herrera M; Barber A; Barría M; Wohllk N
Rev Med Chil; 2008 Sep; 136(9):1107-12. PubMed ID: 19030653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
